FDA-Approved, Compounded, Investigational, or Research-Market Peptides

A status-first guide to terms that are often blurred in peptide marketing.¹²

Regulatory status first

Regulatory categories are not interchangeable. Approval attaches to a specific drug product and labeled use; compounding, clinical investigation, and research-market sale operate under different rules and evidence standards.¹

Evidence category map

“FDA registered facility” does not mean a product is FDA approved.¹²
Compounded drugs are not generic versions automatically equivalent to approved products.¹²
Investigational status does not establish safety or effectiveness.¹

Who this is for

Women navigating midlife health decisions and the clinicians or reviewers helping them evaluate evidence and uncertainty.

What the evidence can support

Drugs@FDA identifies approved drug products and current labels.¹²
ClinicalTrials.gov can show registered research but not prove success.¹
FDA warning letters and compounding pages document enforcement and safety concerns.¹²

What remains uncertain

Regulatory status can change and must be checked near publication.¹²
Marketing language may omit route- or formulation-specific distinctions.¹
State pharmacy rules and federal law can interact.¹

Verification steps

Record exact product, active ingredient, formulation, route, and claimed use.
Verify approval in Drugs@FDA rather than relying on a seller.
Check current FDA sources for the exact product and intended use.

Risks, red flags, and limits

Never infer approval from a facility, ingredient, patent, trial, or COA.¹
This page is educational and not legal advice.
Do not use it to source unapproved drugs.

Sources

Evidence and status are separate questions

Layer	Question	Common category error
Product status	Is the exact product approved, compounded, investigational or sold for research?	Treating a facility, ingredient or trial as product approval
Human evidence	Do trials match the molecule, route, population and claimed outcome?	Generalizing from animals, another peptide or another route
Quality	What identity, batch, sterility and endotoxin evidence exists?	Using analytical purity as a synonym for sterile or safe
Personal decision	What established alternatives, risks and monitoring questions matter?	Letting an online claim replace qualified care

This publication provides no dose, cycle, injection technique, seller ranking or procurement path for unapproved investigational products.¹²

Approval, compounding, investigation and research-market sale are not interchangeable. Original editorial diagram; it does not add a clinical claim.

Claim-level source ledger

Evidence used on this page

Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Checked 2026-08-25.
Internal Error (). Checked 2026-08-25.

Interpretation boundary: each source is listed for the statement it supports; population and design limits remain visible.

FDA status snapshot — 22 August 2026

This table records the current FDA compounding-risk page, not a legal conclusion or complete adverse-event review.¹²

Substance	FDA page observation	Publication boundary
BPC-157	Limited safety information; immunogenicity, impurity and API-characterization concerns described.	No human benefit or safety claim.
CJC-1295	Limited clinical data; serious adverse events described.	No sourcing or dosing.
Ipamorelin	Safety concerns and insufficient proposed-route information described.	No standalone or combination endorsement.
GHK-Cu for injection	Limited human safety data described.	Do not generalize from topical cosmetics.
MOTS-c	No human exposure data identified on the page.	Preclinical interest only.
TB-500 fragment	No human exposure data identified on the page.	Do not generalize from broader thymosin literature.

Update rule: check the linked Drugs@FDA record and FDA safety-risk page for the current status. This dated snapshot is not a live monitoring service.

Regulatory reading aid

Four categories that should never be collapsed

Category	What it establishes	What it does not establish
FDA-approved drug	A specific product, indication, labeling and manufacturing review	Approval of every compounded version, off-label claim or chemical relative
Compounded drug	A patient-specific or outsourcing-facility pathway may apply under federal and state rules	FDA premarket approval, equivalence to an approved drug or blanket safety
Investigational product	Study under a defined protocol may be registered or authorized	General sale, proven benefit or routine clinical use
Research-market product	A seller is labeling an item outside ordinary human-drug presentation	Identity, sterility, lawful self-use, clinical evidence or medical suitability

Verify an exact product in Drugs@FDA, examine the precise compounding context in FDA’s compounding resources, and treat trial registration as a research record—not approval.